Worth reading
30Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
51502
¥ thousandWording
Definitive
How definitive the wording is.Recognition of non-operating expenses
Subject Entity
WAKAMOTO PHARMACEUTICAL CO.,LTD. (filing company)
Target Locations / Products
Transfer of product sales
This disclosure05/15/2026
Cause
Associated with the transfer of product sales
Amount of Impact on Business Performance
¥51.502 million (commission fees, non-operating expense)
Accounting period in which recognized
Fiscal year ending March 2026
Impact on Earnings Forecast
The impact on the earnings forecast is not disclosed. The impact on full-year results for the fiscal year ending March 2026 is reflected in the financial results summary disclosed today.
| Item | Details |
|---|---|
| Event name | Recognition of non-operating expenses |
| Subject Entity | WAKAMOTO PHARMACEUTICAL CO.,LTD. (filing company) |
| Target Locations / Products | Transfer of product sales |
| Cause | Associated with the transfer of product sales |
| Amount of Impact on Business Performance | ¥51.502 million (commission fees, non-operating expense) |
| Accounting period in which recognized | Fiscal year ending March 2026 |
| Impact on Earnings Forecast | The impact on the earnings forecast is not disclosed. The impact on full-year results for the fiscal year ending March 2026 is reflected in the financial results summary disclosed today. |
Items this document does not state (18)
Date of occurrenceDate recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Associated with the transfer of product sales.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.